In this issue of Clinical Watch, we discuss the expanded indication for drugs to treat relapsing forms of multiple sclerosis. We suggest criteria for the relaunched IBS-C drug Zelnorm™ and review a clinical trial of a potentially disease-modifying sickle cell disease treatment. Finally, we review claims data to identify patients at risk for a fall.
For more information about a specific topic, please contact Janelle Sheen or Karen Powell. Be sure to stay tuned for future monthly updates. For more information about our solutions, please visit conduent.com/pharmacy solutions.
